The SE of pharmaceutical company BioNTech stated on Thursday that the COVID-19 vaccine developed in association with Pfizer should be as effective in dealing with the Indian variant of COVID-19 as it was with the South African variant. Blood analysis of vaccinated individuals indicated that the antibodies elicited by the jab were able to combat the mutated virus.
Chief Executive Ugur Sahin stated that the company had the opportunity to test the vaccine against more than 30 variants, some of minor threat and others, such as the South African variant, a far more transmissible mutation. The vaccine proved effective against them all so far, despite this particular variant being more transmissible and far deadlier than its parent virus.
#MaltaDaily
Photo Source: Financial Times